Alice Julien-Laferriere
Research Subjects
Research Interests
Alice Julien-Laferriere has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Valdeolivas
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
1 shared publication - Amy Ann Lo
Genentech Inc., South San Francisco, California
1 shared publication - Angelika Lahr
Roche Innovation Center Munich, Nonnenwald 2, 82377 Penzberg, Germany
1 shared publication - Bettina Amberg
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland
1 shared publication - Björn Jacobsen
Pharmaceutical Sciences, Therapeutic Modalities, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Grenzacherstrasse 124, Basel, Switzerland
1 shared publication - Chia Huey Ooi
Roche Innovation Center Basel, Pharmaceutical Sciences, Pharma Research and Early Development, 4070 Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
Charting the Heterogeneity of Colorectal Cancer Consensus Molecular Subtypes using Spatial Transcriptomics
The heterogeneity of colorectal cancer (CRC) contributes to substantial differences in patient response to standard therapies. The consensus molecular subtypes (CMS) of CRC is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumoral heterogeneity restricts its clinical application, stressing the necessity of further characterizing the composition and architecture of CRC. Here, we used Spatial Transcriptomics (ST) in combination with single-cell RNA sequencing (scRNA-seq) to decipher the spatially resolved cellular and molecular composition of CRC. In addition to mapping the intratumoral heterogeneity of CMS and their microenvironment, we identified cell communication events in the tumor-stroma interface of CMS2 carcinomas. This includes tumor growth-inhibiting as well as -activating signatures, such as the potential regulation of the ETV4 transcriptional activity by DCN or the PLAU-PLAUR ligand-receptor interaction. Our data show the power of ST to bring the CMS-based classification of CRC to another level and thereby gain useful molecular insights for personalized therapy.
Open AccessCharting the Heterogeneity of Colorectal Cancer Consensus Molecular Subtypes using Spatial Transcriptomics
The heterogeneity of colorectal cancer (CRC) contributes to substantial differences in patient response to standard therapies. The consensus molecular subtypes (CMS) of CRC is the most widely-used gene expression-based classification and has contributed to a better understanding of disease heterogeneity and prognosis. Nevertheless, CMS intratumoral heterogeneity restricts its clinical application, stressing the necessity of further characterizing the composition and architecture of CRC. Here, we used Spatial Transcriptomics (ST) in combination with single-cell RNA sequencing (scRNA-seq) to decipher the spatially resolved cellular and molecular composition of CRC. In addition to mapping the intratumoral heterogeneity of CMS and their microenvironment, we identified cell communication events in the tumor-stroma interface of CMS2 carcinomas. This includes tumor growth-inhibiting as well as -activating signatures, such as the potential regulation of the ETV4 transcriptional activity by DCN or the PLAU-PLAUR ligand-receptor interaction. Our data show the power of ST to bring the CMS-based classification of CRC to another level and thereby gain useful molecular insights for personalized therapy.
- Open Access
- 1 February 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (2) , 100984
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
- 1 February 2021
- Published by Elsevier in Translational Oncology
- Vol. 14 (2) , 100984
Open AccessVanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies